Dual targeted therapy with biologic agents and small molecules in refractory inflammatory arthritis: clinical outcomes and safety profile

Key Points

• Improved clinical outcomes were observed in patients receiving dual targeted therapy for inflammatory arthritis.
• The safety profile indicated low adverse events, with only 10% experiencing significant side effects from treatment.
• Observational analysis assessed patient responses to both biologic agents and small molecules over a 6-month period.
• Results highlight the need for more comprehensive trials to validate dual therapy's effectiveness and safety in broader populations.